This activity is part of the Frankly Speaking with Dr. Frank Domino podcast series.
Frankly Speaking CME 249

Podcast

Using DOACs for Valvular Atrial Fibrillation - Frankly Speaking EP 249Guest: Alan M. Ehrlich, MD, FAAFP
Music Credit: Richard Onorato

For non-valvular atrial fibrillation, physicians, patients, and guideline organizations all prefer direct oral anticoagulants (DOACs) over vitamin K antagonists, such as warfarin, for thromboembolic prophylaxis. For those with valvular atrial fibrillation, the data for safety and efficacy have been limited because randomized trials comparing DOACs to warfarin often exclude patients with valvular atrial fibrillation. Join us to explore new data that sheds light on the use of DOACs in valvular atrial fibrillation.

Episode References and Resources: 

  • Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study. Ann Intern Med. 2021;174(7):910-919. 

Begin

Already listened on another platform?

Claim Credits

CME/CE Information

0 Credits - Not for CME/CE Credit

Release Date: 11/8/2021

Expiration Date: 11/8/2022

Learning Objectives

  • Assess the data supporting the use of DOACs for valvular atrial fibrillation
  • Discuss how to counsel patients on the benefits and risks of DOACs for atrial fibrillation
     

     

     

 

Faculty

Frank J. Domino, MD

Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA

Learn More

Alan M. Ehrlich, MD, FAAFP

Associate Professor of Family Medicine and Community Health, University of Massachusetts Medical School,
Executive Editor, DynaMed 

Learn More

Supporters and Partners

Commercial Supporter

Not Applicable

Education Partner

Not Applicable

Using DOACs for Valvular Atrial Fibrillation - Frankly Speaking EP 249

Begin